Cargando…

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.

Cancer chemotherapy interacts with cell proliferation, but data on the relationship between cancer cell replication and the effect of adjuvant chemotherapy are scarce. We have investigated the S-phase fractions of the primary tumour from premenopausal breast cancer patients who participated in a ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stål, O., Skoog, L., Rutqvist, L. E., Carstensen, J. M., Wingren, S., Sullivan, S., Andersson, A. C., Dufmats, M., Nordenskjöld, B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033711/ https://www.ncbi.nlm.nih.gov/pubmed/7981085

Ejemplares similares

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer
por: Stal, O, et al.
Publicado: (2000)

Akt kinases in breast cancer and the results of adjuvant therapy
por: Stål, Olle, et al.
Publicado: (2003)

Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.
por: Wingren, S., et al.
Publicado: (1994)

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.
por: Stål, O., et al.
Publicado: (1992)

Frequent allelic losses at 11q24.1–q25 in young women with breast cancer: association with poor survival
por: Gentile, M, et al.
Publicado: (1999)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
por: Wegman, Pia, et al.
Publicado: (2007)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

DNA ploidy and S-phase fraction as prognostic factors in patients with uveal melanomas.
por: Karlsson, M., et al.
Publicado: (1995)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors
por: Sobash, Philip T., et al.
Publicado: (2022)

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
por: Rosell, J, et al.
Publicado: (2011)

Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study
por: Chen, Zhiju, et al.
Publicado: (2020)

Adjuvant radiotherapy and chemotherapy in breast cancer: 30 year follow-up of survival
por: McArdle, Colin S, et al.
Publicado: (2010)

Preoperative Splenic Density for the Prediction of Survival and Adjuvant Chemotherapy Benefits in Gastric Cancer
por: Zhang, Wei-teng, et al.
Publicado: (2020)

Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer
por: Lee, Mok-Won, et al.
Publicado: (2021)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
por: Nordenskjöld, Anna, et al.
Publicado: (2023)

No survival benefit could be obtained from adjuvant radiotherapy in esophageal cancer treated with neoadjuvant chemotherapy followed by surgery: A SEER-based analysis
por: Zheng, Si-Yue, et al.
Publicado: (2022)

Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer
por: Liu, Qi, et al.
Publicado: (2019)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients
por: Bayoumi, Yasser, et al.
Publicado: (2014)

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
por: Sivik, Tove, et al.
Publicado: (2012)

Pathology of rectal adenocarcinoma following preoperative adjuvant radiotherapy and chemotherapy.
por: Allen, D. C., et al.
Publicado: (1999)

Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy
por: Hsieh, Mao‐Chih, et al.
Publicado: (2018)

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
por: Kümmel, S, et al.
Publicado: (2006)

Adjuvant chemotherapy does not provide survival benefits to elderly patients with stage II colon cancer
por: Lee, Kil-yong, et al.
Publicado: (2019)

No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer
por: Kang, Nai-Wen, et al.
Publicado: (2022)

Survival benefits and challenges of adjuvant chemotherapy for high-grade osteosarcoma: a population-based study
por: Wang, Jinkui, et al.
Publicado: (2023)

Adjuvant single-fraction radiotherapy is safe and effective for intractable keloids
por: Song, Changhoon, et al.
Publicado: (2014)

On the utility of the lognormal model for analysis of breast cancer survival in Sweden 1961-1973.
por: Rutqvist, L. E.
Publicado: (1985)

DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.
por: Karlsson, M., et al.
Publicado: (1993)

Oxaliplatin-Based Adjuvant Chemotherapy without Radiotherapy Can Improve the Survival of Locally-Advanced Rectal Cancer
por: Li, Jun, et al.
Publicado: (2014)

Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis
por: Yang, Ya’nan, et al.
Publicado: (2015)

Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer
por: Van Laar, Ryan K
Publicado: (2012)

Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?
por: Liu, Yutao, et al.
Publicado: (2017)

Correction: Survival benefits and challenges of adjuvant chemotherapy for high-grade osteosarcoma: a population-based study
por: Wang, Jinkui, et al.
Publicado: (2023)

Comparison of Survival Benefits of Combined Chemotherapy and Radiotherapy Versus Chemotherapy Alone for Uterine Serous Carcinoma: A Meta-analysis
por: Lin, Yanying, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_flropuvm69chi1q822khir68he